Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What Does Chill Mean?
Special restrictions that can be placed on a given security by the Depository Trust Company (DTC). Chill restrictions are intended to limit the potential for problems within the financial marketplace, and can be placed on a security for various reasons.
Investopedia explains Chill
Owned by many financial companies including the New York Stock Exchange (NYSE), the DTC acts as a clearinghouse for stock exchange securities, settling trades in corporate and municipal securities. If the DTC has cause to be concerned about a specific security currently processed through its system, it may place a "chill" status on the security. This will restrict brokerages' ability to transfer the shares or units of the security through DTC until the security's issues are cleared up or it ceases trading on the market.
Read more: http://www.investopedia.com/terms/c/chill.asp#ixzz1eRsYhUZm
halpern capital:Case Study: Nutracea Inc.
We raised approximately $26M in two private transactions.
Senior bankers at Halpern Capital were able to clearly communicate the business plan and potential for future success to investors, despite limited historical revenue, profits and growth.
High caliber institutional investors participated in the funding including Angelo Gordon, Pinnacle Fund, Walker Smith and Pequot Capital*.
During the course of the road show, the deal was shown to over 40 institutions.
Who ever said it would be under $1.00
http://www.anl.gov/
Argonne's scientific and technological initiatives aim to solve the nation's energy, environmental and security challenges
http://henkhoogenkamp.com/Link.aspx
Henk Hoogenkamp's book is on the scroll of http://www.nutracea.com/.
Our time is coming!!!!!!!!!!!!!!!!!!!
Please provide your source of information about no clinical trials!
Please provide your source of information about no clinical trials!
How do you know that they have stopped clinical trials?
http://www.evaluatepharma.com/Universal/View.aspx?type=Entity&entityType=Product&id=36011&lType=modData&componentID=1002#&&_ViewArgs=%7b%22_EntityType%2
A Doctor's Testimony - Rice Bran Health Benefits
"I came across NutraCea through the internet. I have been using it in my office with patients since Dec. 2009. I started reading about the benefits of stabilized rice bran to help with cholesterol and blood sugar."
"Having pre-biotic qualities, no trans-fats, gluten-free along with high levels of antioxidants and omega's I was curious about the product line. I have tried many products from many companies over the 20+ years in practice and I'm usually very skeptical about most products..."
Find Out Why This Doctor Recommends Rice Bra
Walter F Leise III’s Experience
Senior Researcher
Abbott Laboratories
(Public Company; ABT; Medical Devices industry)
June 2006 — Present (4 years 7 months)
• • Manage and direct the research of several scientists, Master and Ph.D. Level.
• Coordinate 10-20 global collaborations with multiple target-discovery efforts and support groups.
• Develop innovative solutions to complex problems and business challenges to improve productivity and reproducibility.
• Conduct 2-5 projects simultaneously that support project teams by providing technical expertise and guidance in addition actual purified recombinant proteins, recombinant molecules, and therapeutic antibodies.
• Design, generate, optimize, and characterize recombinant proteins/therapeutic antibodies.
• During a 4 months period, I cloned and expression tested 400 human and mouse genes to identify novel targets.
• Catalyzed the continued development of an expression method that allows a protein complex, such as an antibody, to be expressed from a single open reading frame. The antibodies created during this screen were examined with three ELISA assays I optimized.
• Developed high-throughput antibody cloning platform using novel molecular techniques.
The company disclosed the offerings in filings with the US Securities and Exchange Commission. Principals cited in the filings are Walter F. Leise III from Abbot Laboratories and Denis Keyes, Fred Brown and Walter F. Leise Jr.
Earlier in December, Sarasota Medical signed a binding letter of Intent with Durham, NC-based Oxygen Biotherapeutics (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) to determine the feasibility of pursuing a joint research and development venture for treating chronic ischemic wounds.
Oxygen Biotherapeutics’ Wundecyte product is a novel gel under development. It is designed to be used as a wound-healing agent that delivers oxygen to a wound alone, or in combination with a specialized oxygenating bandage.
SMP’s oxygen delivery devices include WoundSeal I, a chambered device specifically designed to deliver liquids and gels to a wound surface; WoundSeal II, a dressing with a plurality of layers designed to deliver one or more beneficial materials to the skin for the treatment of chronic wounds and burns; and OxyShield, a topical oxygen chamber designed to deliver hyperbaric oxygen to acute and chronic wounds to aid in initiating angiogenesis. Patents are filed for all three devices.
The company does not appear to have a Web site.
Sarasota Medical raises $1.1M, launches new $4M offering
December 16th, 2010
SARASOTA, FL – Sarasota Medical Products, an early-stage company developing products for wound and ostomy care, has raised $950,000 from 10 investors and opened a second equity offering with $150,000 toward a targeted $4 million round, according to regulatory filings.
The company was founded in January 2010 by developers of current products and processes used in wound and ostomy care. It has developed four new products. According to Sarasota news reports, the company plans to hire up to 60 people over the next five years at an average salary of $50,000 a year.
Most will think that there is something wrong with his "ticker"!!!!
Arteriocyte, a clinical stage Biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts, is developing proprietary stem cell and tissue engineering based therapies. Arteriocyte’s goal is to develop commercially available stem cell based therapies using multiple sources of adult derived stem cells (marrow, peripheral cord blood, and cartilage) for disease where surgical interventions are inadequate.
In 2007, Arteriocyte partnered with DW Healthcare Partners and Comerica to create Arteriocyte Medical Systems, in order to develop and acquire novel medical devices and point of care surgical solutions. Arteriocyte is developing new treatment strategies that couple its novel cellular therapies with the innovative delivery platforms commercially available through Arteriocyte Medical Systems.
www.youtube.com/v/uDhL--RLzoU
WOW !!!!!!!!!!!!!!!!!!
LITTLE FALLS, NJ, Dec 30, 2009 (MARKETWIRE via COMTEX) -- mPhase Technologies,
Inc. (OTCBB: XDSL), the global leader in the development of Power On Command(TM)
reserve battery technology, today announced that its consumer products division,
mPower Technologies Inc., will unveil the mPower Emergency Illuminator(TM) at
the 2010 International Consumer Electronics Show in Las Vegas, Nevada. The
Emergency Illuminator will be shown during the CES Unveiled media event on
January 5, 2010 as well as on press day, January 6, 2010. The illuminator will
subsequently be on public display at CES from January 7-10, 2010.
Designed by Porsche Design Studio of Zell am See, Austria, and manufactured by
MKE of Austria, the mPower Emergency Illuminator is a precision instrument with
a powerful 180 Lumens LED and two separate battery tubes. One tube is for
everyday use and holds two CR123 batteries, while the other tube holds mPhase's
Power On Command(TM) Reserve Battery. If the regular CR123 batteries run down,
the Reserve Battery takes over -- even after laying idle for 20 years. The
Emergency Illuminator also features a USB port, that can be used for charging
portable devices such as a cell phone.
"The mPower Emergency Illuminator is a precision engineered tool," said Ron
Durando, CEO of mPhase Technologies. "It is the first product to put our Power
On Command reserve battery technology into the hands of the consumer. The
extraordinarily long shelf life of the reserve battery guarantees users a
reliable source of power when they need it most."
mPhase Technologies has been named an International Consumer Electronics Show
Innovations 2010 Design and Engineering Awards honoree. The Company expects the
mPower Emergency Illuminator to become available for purchase in January 2010
with delivery in March 2010 and to retail at a price of $289.00.
A universal glove box bracket will also be available for $29.99, allowing for
easy mounting in most automobile glove compartments.
Great Article
www.nutracea.com/StabilizedRiceBran/
Radio In Vivo December 16, 2009 Guests: Dr. Chris Stern, Chairman and CEO, and Deb Thompson, Sr. VP Clinical Affairs, Oxygen Biotherapeutics, Inc., Durham Topic: Oxygen Biotherapeutics' oxygen therapy products in development for traumatic brain injury, stroke, heart attack, and many other biomedical applications
http://home.earthlink.net/~radioinvivo/id1.html
Reasons We Expect to Restructure Successfully
What is CSR?
Reasons For Success
NutraCea CSR Information
Our Assets Significantly Exceed Our Liabilities. On 11/10/2009 the book value of our assets was $83.8 million compared to $18.9 million in liabilities.
We have signed a Debtor-in-Possession (DIP) financing for $6,750,000 with Wells Fargo Bank, NA acting through it's Wells Fargo Business Credit operating division. This provides additional liquidity of more than $3 million over and above the outstanding loan balance of $3,575,000.
Our revised business strategy, focused on our core businesses of SRB, RBO/DRB, nutraceuticals and baby cereal, will simplify execution and reduce overhead.
WUNDECYTE
The company has made a gel from OXYCYTE that it believes can be useful in treating wounds by supplying oxygen to injured tissue from the outside in. When a wound heals, the speed of healing is largely dependant on how much oxygen the key tissues get during their healing phase. The company believes that OXYCYTE can dramatically increase the speed of oxygen delivery, thereby increasing the speed of the healing.
The company has conducted safety studies and plans an FDA filing for clinical trials related to this indication in late 2009.
Dr. Bruce D. Spiess, MD, a member of the company's board of directors and co-chair of the company's Medical Advisory Board explains the potential role of OXYCYTE in wound treatment in these videos.
VitaVent
The company has submitted a patent application for a new invention that uses Oxycyte™ perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. The patent application is also an improvement of the existing Fluorovent patent the company already possesses.
The invention, VitaVent™, provides an immediate supply of Oxycyte and oxygen to the victim of a heart attack or stroke until medical help is available. It may be easily used by a person who has suffered a heart attack or stroke, but is still conscious, without the assistance of another. It may also be used easily by someone who cannot adequately perform CPR in order to assist someone who is unconscious.
By safely combining Oxycyte and oxygen in a device without pressure, and administering both together with the help of a self-propelled compressor, Oxycyte is able to absorb and carry into the victim’s lungs an oxygen load that is 50 times greater than what the same volume of blood is able to carry. The concept of this invention is to administer oxygen-enriched Oxycyte through the lungs to reach oxygen-deprived tissues even when circulation is obstructed and/or a person has stopped breathing.
The company believes this device could be sold over the counter and be present wherever there is a defibrillator as well as in any home where there is concern about a potential heart attack or stroke for a loved one.
[/bOxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
Press Release
Source: Oxygen Biotherapeutics, Inc.
On 11:08 am EST, Friday December 4, 2009
Buzz up! Print
Companies:Oxygen Biotherapeutc
DURHAM, N.C., Dec. 4 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT - News) today announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM) emulsion in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.
"This trial is of invaluable importance in improving the outcome of patients with severe TBI. We hope to finally prove that there is a safe and effective treatment for this devastating injury," said Chris Stern, company chairman and CEO. "I know that our shareholders have been wondering why it has taken so long to dose the first patient. It has taken longer than expected due to important training and logistical considerations at the trial sites. Those are being resolved on a site-by-site basis and enrollment should now start progressing. I'll go into more detail on that in my blog over the weekend. But I have to emphasize that our main criterion in the trial is safety. We therefore intentionally did not rush enrollment in the early stage. Our early competitors showed us how dangerous it is to rush a trial. We will not do that."
Out of respect for the privacy of the patients and their families, the company will not be disclosing any identifying information about patients in the study or the type of accident that caused the TBI.
The company has named the 128 patient study "Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury" or "STOP TBI". Since study participants will all be emergency cases, it is not possible to predict the precise timing of the flow of patients into the study, which is being supervised by a contract research organization, PFC Pharma Focus AG. The principal investigator is Dr. Michael Reinert of the Department of Neurosurgery at the University Hospital of Berne.
The dose escalation studies will focus on finding the lowest dose of Oxycyte that provides clinical benefit in traumatic brain injury while minimizing adverse effects. Dose levels of Oxycyte will start at 1.0 ml/kg body weight and escalate in steps to 2.0 ml/kg, and 3.0 ml/kg for subsequent patient cohorts. Escalation of dose will only occur after a favorable review of safety data by an independent Data Safety Monitoring Board.